News

22 May 2024

MedTech Strategist Features RebrAIn’s Precision Targeting Solutions for Parkinson’s Disease

We are delighted to share that MedTech Strategist has featured RebrAIn in their latest issue.

The article explores how our supervised AI-driven platform, OptimMRI, simplifies precision targeting for Deep Brain Stimulation (DBS) in Parkinson’s Disease. By enhancing accuracy and reducing costs, RebrAIn aims to make DBS procedures faster, safer, and more accessible. Our innovative approach is set to transform neurosurgical practices, offering improved outcomes for patients.

Read more about our advancements and future plans in the full PDF version of the article.

back to the news page

More news

RebrAIn Co-Founders to Present Innovative VIM Targeting Techniques at WSSFN Biennial Meeting

Sep 3, 2024

RebrAIn is excited to announce that its co-founders, Prof. Emmanuel Cuny, MD, and Prof. Nejib Zemzemi, PhD, will be presenting groundbreaking research on VIM targeting techniques at the upcoming World Society for Stereotactic and Functional Neurosurgery (WSSFN)...

RebrAIn Achieves Second FDA 510(k) Clearance, Advancing AI-Powered Neurosurgical Targeting

Aug 13, 2024

RebrAIn is proud to announce its second FDA 510(k) clearance for the OptimMRI software, marking another significant milestone in our mission to revolutionize neurosurgical targeting through cutting-edge AI technology. This clearance expands our capabilities to assist...

Focused Ultrasound Foundation Highlights RebrAIn’s AI Innovations in Neurosurgery

May 9, 2024

We are excited to share that the Focused Ultrasound Foundation has featured RebrAIn for our pioneering use of artificial intelligence in brain targeting. The article details how our supervised AI-driven platform, Optim MRI, enhances precision and effectiveness in...